Selective Editing of the Mutant Huntingtin Gene
Selective Editing of the Mutant Huntingtin Gene
批准号:
10381659
负责人:
NEIL ARONIN
金额:
$47.12万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-04-01 至 2024-03-31
关键词:
AffectAgeAllelesAmyotrophic Lateral SclerosisAnimal ModelAntisense OligonucleotidesBehavioralBrain DiseasesBrain regionCAG repeatCRISPR/Cas technologyCare given by nursesCharacteristicsChildClustered Regularly Interspaced Short Palindromic RepeatsCodeDNA Binding DomainDataDementiaDetectionDevelopmentDiagnosisDiscipline of NursingDiseaseDyskinetic syndromeEconomic BurdenEconomicsEndonuclease IEquilibriumExonsFamilyFrameshift MutationFrontotemporal DementiaGenesGeneticGenetic PolymorphismGenetic TranscriptionGoalsGross National ProductGuide RNAHeadHealth BenefitHeterozygoteHumanHuman Cell LineHuntington DiseaseHuntington geneHuntington proteinImpaired cognitionIndividualInheritedKnock-inKnock-in MouseLaboratoriesLengthMeasurementMental DepressionMessenger RNAMicroRNAsModelingMovementMovement DisordersMusMutationNeostriatumNerve DegenerationNeuronsNuclearOutcomeParentsPathogenesisPathogenicityPathologicPatientsProductionProtein FragmentProteinsPublic HealthPublishingSingle Nucleotide PolymorphismSmall Interfering RNASocietiesStressTestingTherapeuticTimeUntranslated RegionsWestern BlottingWorkbaseimprovedin vivomRNA Surveillancemotor impairmentmouse modelmutantnervous system disorderneuropathologynovelnucleasepreventprogramspromoterpublic health relevancerepairedsuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The cause of Huntington’s disease is an increase in the trinucleotide CAG repeat from under 36
repeats to 36 or greater repeats. The mode for the number of repeats is 42, and most patients have between
40 and 45. The disease generally starts between ages 30 and 40, with onset and progression of impaired
cognition, depression, and aberrant movement. The genetics is autosomal dominant. With gene editing, we
aim to eliminate expression of the mutant allele of Huntington’s disease or repair the mutation by reducing the
number of CAG repeats. We will use CRISPR-Cas9 for selective targeting of single nucleotide polymorphisms
with heterozygosities to prevent the mutant huntingtin allele from producing protein. Generating frameshift
mutations at the SNP heterozygosity reduces mutant huntingtin protein, with no production of mutant protein
fragments. In a second approach, we reduce the number of CAG repeats from a high number in the mutant
allele to a healthy number of CAG repeats, through the use of Cas9 nickases. The nickase Cas9D10A is used to
reduce the CAG repeat number below the pathogenic threshold. We have preliminary data that supports each
aspect of the proposal. The goal of this discovery application is to set the stage for promising therapeutics for
treatment of Huntington’s disease and other autosomal dominant neurological disorders caused by
trinucleotide CAG repeat expansions.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Advancing RNA Therapeutics for Huntington's Disease
-
批准号:10440776
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2021
-
负责人:NEIL ARONIN
-
依托单位:
Advancing RNA Therapeutics for Huntington’s Disease
-
批准号:10608177
-
项目类别:
-
资助金额:$130.16万
-
财政年份:2020
-
负责人:NEIL ARONIN
-
依托单位:
Advancing RNA Therapeutics for Huntington’s Disease
-
批准号:10087978
-
项目类别:
-
资助金额:$150.58万
-
财政年份:2020
-
负责人:NEIL ARONIN
-
依托单位:
Advancing RNA Therapeutics for Huntington’s Disease
-
批准号:10359054
-
项目类别:
-
资助金额:$125.61万
-
财政年份:2020
-
负责人:NEIL ARONIN
-
依托单位:
Selective Editing of the Mutant Huntingtin Gene
-
批准号:9906917
-
项目类别:
-
资助金额:$46.53万
-
财政年份:2018
-
负责人:NEIL ARONIN
-
依托单位:
Exosome based therapeutics in Huntington's disease
-
批准号:8963652
-
项目类别:
-
资助金额:$98.81万
-
财政年份:2013
-
负责人:NEIL ARONIN
-
依托单位:
Exosome based therapeutics in Huntington's disease
-
批准号:8581918
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2013
-
负责人:NEIL ARONIN
-
依托单位:
Exosome based therapeutics in Huntington's disease
-
批准号:8845792
-
项目类别:
-
资助金额:$8.38万
-
财政年份:2013
-
负责人:NEIL ARONIN
-
依托单位:
Exosome based therapeutics in Huntington's disease
-
批准号:9325094
-
项目类别:
-
资助金额:$97.24万
-
财政年份:2013
-
负责人:NEIL ARONIN
-
依托单位:
Exosome based therapeutics in Huntington's disease
-
批准号:8711588
-
项目类别:
-
资助金额:$49.76万
-
财政年份:2013
-
负责人:NEIL ARONIN
-
依托单位:
SIGNALING MECHANISMS IN NEURONAL DEGENERATION
-
批准号:2904504
-
项目类别:
-
资助金额:$38.32万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
Signaling Mechanisms in Neuronal Degeneration
-
批准号:8259797
-
项目类别:
-
资助金额:$56.49万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
SIGNALING MECHANISMS IN NEURONAL DEGENERATION
-
批准号:6394047
-
项目类别:
-
资助金额:$39.28万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
SIGNALING MECHANISMS IN NEURONAL DEGENERATION
-
批准号:6639552
-
项目类别:
-
资助金额:$43.41万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
SIGNALING MECHANISMS IN NEURONAL DEGENERATION
-
批准号:6540040
-
项目类别:
-
资助金额:$40.14万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
SIGNALING MECHANISMS IN NEURONAL DEGENERATION
-
批准号:6187930
-
项目类别:
-
资助金额:$38.22万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
Signaling Mechanisms in Neuronal Degeneration
-
批准号:6968840
-
项目类别:
-
资助金额:$36.6万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
Signaling Mechanisms in Neuronal Degeneration
-
批准号:8462691
-
项目类别:
-
资助金额:$55.36万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
Signaling Mechanisms in Neuronal Degeneration
-
批准号:7091480
-
项目类别:
-
资助金额:$34.44万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
Signaling Mechanisms in Neuronal Degeneration
-
批准号:7454318
-
项目类别:
-
资助金额:$33.44万
-
财政年份:1999
-
负责人:NEIL ARONIN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: